↓ Skip to main content

Molecular Radio-Oncology

Overview of attention for book
Attention for Chapter 3: Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology
Altmetric Badge

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
9 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology
Chapter number 3
Book title
Molecular Radio-Oncology
Published in
Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, January 2016
DOI 10.1007/978-3-662-49651-0_3
Pubmed ID
Book ISBNs
978-3-66-249649-7, 978-3-66-249651-0
Authors

Shyhmin Huang, H. Peter Rodemann, Paul M. Harari, Huang, Shyhmin, Peter Rodemann, H., Harari, Paul M.

Abstract

Ionizing radiation has been shown to activate and interact with multiple growth factor receptor pathways that can influence tumor response to therapy. Among these receptor interactions, the epidermal growth factor receptor (EGFR) has been the most extensively studied with mature clinical applications during the last decade. The combination of radiation and EGFR-targeting agents using either monoclonal antibody (mAb) or small-molecule tyrosine kinase inhibitor (TKI) offers a promising approach to improve tumor control compared to radiation alone. Several underlying mechanisms have been identified that contribute to improved anti-tumor capacity after combined treatment. These include effects on cell cycle distribution, apoptosis, tumor cell repopulation, DNA damage/repair, and impact on tumor vasculature. However, as with virtually all cancer drugs, patients who initially respond to EGFR-targeted agents may eventually develop resistance and manifest cancer progression. Several potential mechanisms of resistance have been identified including mutations in EGFR and downstream signaling molecules, and activation of alternative member-bound tyrosine kinase receptors that bypass the inhibition of EGFR signaling. Several strategies to overcome the resistance are currently being explored in preclinical and clinical models, including agents that target the EGFR T790 M resistance mutation or target multiple EGFR family members, as well as agents that target other receptor tyrosine kinase and downstream signaling sites. In this chapter, we focus primarily on the interaction of radiation with anti-EGFR therapies to summarize this promising approach and highlight newly developing opportunities.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 9 100%

Demographic breakdown

Readers by professional status Count As %
Professor 2 22%
Student > Ph. D. Student 2 22%
Researcher 2 22%
Other 1 11%
Unknown 2 22%
Readers by discipline Count As %
Medicine and Dentistry 4 44%
Biochemistry, Genetics and Molecular Biology 2 22%
Agricultural and Biological Sciences 1 11%
Unknown 2 22%